Innovate Nordics is aimed at Nordic growth companies with ambitions to establish themselves in the US market. After a selection process, Neogap has been selected as one of the companies that will benefit from market insights, business development support and investor networking in the US during the year. The program includes virtual workshops, a kickoff in Stockholm and a finale in New York in May.

“We are honored to have been selected for Innovate Nordics 2025. The program gives us a valuable opportunity to deepen our contacts, build new relationships, and increase our access to the US market. Every step we take brings us closer to our goal – to make personalized cancer immunotherapy available to more patients,” says Andrea Salmén, COO at Neogap Therapeutics.

During the spring, Neogap will participate in the program launch with a kickoff on May 8 in Stockholm, followed by a delegation to New York on May 19–21 where the company will present its work at the Grand Pitch Finale to investors and partners.